News Archive

Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.

Showing 1199 results

March 2019

Key ReleaseMar 22, 2019
Novartis plans for Alcon spin-off on April 9, 2019
Alcon obtained approval for listing on SIX Swiss Exchange and New York Stock Exchange Alcon will seek effectiveness of Form 20-F registration statement from the US Securities and Exchange…
Media ReleaseMar 18, 2019
Alcon Announces Acquisition of PowerVision, Inc.
Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
Media ReleaseMar 14, 2019
Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy
Study is planned to assess efficacy and safety of Entresto® (sacubitril / valsartan) vs enalapril in 900 patients with chronic Chagas cardiomyopathy; recruitment is planned to commence within 2019…
Key ReleaseMar 14, 2019
Novartis announces change in Sandoz leadership
Richard Francis, CEO Sandoz, to step down on March 31, 2019 Francesco Balestrieri, Head Region Europe, Sandoz, appointed ad-interim CEO Sandoz Basel, March 14, 2019 - Novartis announced…
Media ReleaseMar 11, 2019
Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW
Sandoz commits to increasing support from one winner to three, following impressive pitches from the finalists Winning ideas proposed innovative uses of artificial intelligence, mobile apps and…
Media ReleaseMar 05, 2019
Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16…
Media ReleaseMar 04, 2019
Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early…

March 2019

Novartis plans for Alcon spin-off on April 9, 2019

Alcon Announces Acquisition of PowerVision, Inc.

Novartis joins the Global Chagas Disease Coalition and also announces first multinational, prospective, randomized study in people with chronic Chagas cardiomyopathy

Novartis announces change in Sandoz leadership

Three winners of 2019 Sandoz Healthcare Access Challenge (HACk) are announced at SXSW

Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®*

Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China

February 2019

Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting

Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrates gut

Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale

Novartis issues summary financial information for the Alcon eye care business ahead of shareholder vote on proposed spin-off

Novartis to pursue transformational therapy to reduce risk of cardiovascular disease in people living with elevated levels of inherited lipoprotein(a)